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52 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3applied LOOCV, we were able to correctly predict the tumor
behavior (T-level down-sizing) in 83% of patients (p = 0.02). We
then observed that after a median follow-up of 34.5 months, all
five patients with metastatic disease belonged to the group of
non-responders. We again applied LOOCV and correctly predicted
all five patients with recurrence. Furthermore, all 11 patients who
were predicted to remain cancer free showed no evidence of
recurrence.
Conclusion: Our results suggest that pretherapeutical gene
expression profiling may assist in response prediction of rectal
adenocarcinomas to preoperative CT/RT and in prediction of dis-
ease free survival if validated in larger independent studies.
doi:10.1016/j.ejcsup.2006.04.127
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Background: Colorectal carcinomas develop through the
sequential stages of increasing morphological and molecular
alterations. While the correlation of tumor phenotype with asso-
ciated genomic alterations has been firmly established, the corre-
lation with global gene expression profiles is less.
Methods: We analyzed tissue samples from 36 patients to iden-
tify sequential alterations of the genome and transcriptome that
define the transformation of normal epithelium and the progres-
sion from adenomas to invasive disease.
Results: Comparative genomic hybridization (CGH) revealed pat-
terns of stage specific, recurrent genomic imbalances. Gene
expression analysis on 9K cDNA arrays identified 58 genes to be
differentially expressed between normal mucosa and adenoma,
116 genes between adenoma and carcinoma, and 158 genes
between primary carcinoma and liver metastasis (p < 0.001). Our
analysis revealed a direct correlation of chromosomal copy num-
ber changes with chromosome-specific average gene expression
levels.
Conclusion: Increasing genomic instability, a recurrent pattern
of chromosomal aberrations and a specific gene expression pat-
tern correlate with distinct stages of colorectal cancer progres-
sion. Chromosomal aneuploidies exert a direct effect on average
expression levels of the genes residing on the aneuploid chromo-
somes, thereby contributing to a massive deregulation of the cel-
lular transcriptome. The identification of novel genes and
proteins might deliver relevant molecular targets for diagnostic
and therapeutic interventions.
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Background: Antibodies against the human nuclear antigen pKi-
67 (Ki-67, MIB-1) are routinely used in oncology as immune-histo-
logical proliferation marker. PKi-67 is exclusively expressed in all
active phases of the cell cycle (G1,S, G2, Mitosis). The Ki-67 index
(relative number of positive stained nuclei) serves as an indepen-
dent prognostic marker for certain tumor entities. We investigated
whether colorectal cancer patients express auto-antibodies
against pKi-67 and whether this has a prognostic relevance.
Methods: Auto-antibodies were detected by Western blot stain-
ings from SW480 nuclear extracts with 36 pre- and 65 post-oper-
ative sera of colorectal cancer patients’ sera. Sera of 20 voluntary
healthy donors served as negative control. The same samples
were simultaneously tested for p53 auto-antibodies.
Results: Thirteen percent of the sera proved to be positive for
pKi-67 auto-antibodies while the control sera were completely
negative. p53 auto-antibodies could be found in 53% of the patient
sera. 75% anti-pKi-67 positive samples were also anti-p53 posi-
tive. For both antigens we found less positive antibodies in
post-operative sera (pKi-67: 9%; p53: 42%) than in pre-operative
sera (pKi-67: 19%, p53: 61%). There was, however, no significant
correlation between pKi-67 positive sera and tumor stage (I:
13%, II: 4%; III: 23%; IV: 13%), grading or patient’s prognosis.
Remarkably, there is a significant (p = 0,023) correlation of pKi-
67 positive sera of colon cancer patients (77%) in comparison to
rectal cancer patients (60%).
Conclusion: PKi-67 auto-antibodies could be diagnostically valu-
able in the early detection of neoplasia and could be used as
potential markers for recurrent or metastatic disease.
doi:10.1016/j.ejcsup.2006.04.129
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Purpose: Prognostic studies on transcription factors acting at
specific promoter elements have never been performed so far.
In previous studies we showed that the invasion-related gene u-
PAR is regulated especially via an AP-2/Sp1(-152/-135)-, and an
AP-1-promoter motif(-190/-171), mediating u-PAR-induction by
E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 53K-Ras and Src. The present study was performed to obtain first
evidence for a prognostic relevance of transcription factors differ-
entially bound to the u-PAR-promoter, and their molecular induc-
ers, in colorectal cancer.
Patients and Methods: Tumors/normal tissues of prospectively
followed 92 patients were analyzed for Src-activity, K-ras-muta-
tions, and transcription factor binding to both u-PAR-promoter
motifs (in vivo-gelshift, kinase-assay, PCR).
Results: Kaplan–Meier analysis (Mantel-Cox) showed a signifi-
cant correlation between elevated binding of Sp1/Sp3 to region -
152/-135 (p = 0.002, p = 0.006), the combinations of Sp1/AP-2 and
Sp1/AP-1 binding to both motifs (p = 0.010, p = 0.005), and Sp1-
binding/high Src-protein in tumors (p < 0.001), with poor survival.
Survival risk increased with the number of bound transcription
factors, the binding of three transcription factors to both u-PAR-
promoter motifs defining a high risk group for survival
(p = 0.021). In multivariate analysis, elevated binding of Sp1, or
combinations of Sp1/AP-2-binding, Sp1/AP-1-binding, or Sp1-
binding/high Src, were new and independent prognostic parame-
ters besides surgical curability, and UICC. A first molecular staging
model (CART) could define new high-risk groups from transcrip-
tion factors bound to specific promoter motifs.
Conclusion: This is the first study to demonstrate an independent
impact on clinical prognosis by transcription factors acting at spe-
cific promoterelements of an invasion-related gene, and mediating
specific signaling, in colorectal cancer. Such analysis can select
new high-risk subgroups for individualized targeting approaches.
doi:10.1016/j.ejcsup.2006.04.130
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LDH is an intracellular enzyme that reflects important biological
processes such as metabolic state, activation status or malignant
process. The spontaneous LDH release from peripheral blood
lymphocytes (PBL) of patients with breast cancer, lymphoma,
head and neck, and malignant melanoma is associated with
advanced clinical stage, bulky tumor mass, reflecting cell mem-
brane alterations, possible by TNF. As breast cancer is a hor-
mone-dependent tumor, in this study we investigate in vitro,
effect of sex steroid hormone, 17-b estradiol, on membrane char-
acteristics of PBL in 37 breast cancer patients relevant to clinical
stage, menopause, Karnofski index before and undergoing
tamoxifen therapy. We found that 17-b estradiol induced an
increase in spontaneous LDH release activity of PBL at dose and
time dependent manner in healthy controls with no changes in
PBL cell cycle phase distribution (determined by Flow cytometry)
and total intracellular LDH activity (determined from separated
lymphocytes after lysis by ultrasound). Spontaneous LDH release
activity from PBL of breast cancer patients with metastatic dis-
ease, undergoing tamoxifen therapy show significant decrease
of spontaneous LDH release activity compared to untreated
patients. In vitro treatment with 17-b estradiol of PBL had no
effect on increase of spontaneous LDH release activity in breastcancer patients undergoing tamoxifen therapy, contrary to
healthy control PBL. Based on these results we show for the first
time that PBL of breast cancer patients undergoing anti-estrogen
therapy show cell membrane stabilization. We conclude that
determination of spontaneous LDH release activity in breast can-
cer patients is valuable in diagnosis and monitoring of the thera-
peutic effect of standard and anti-estrogen therapy.
doi:10.1016/j.ejcsup.2006.04.131
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Background: Preoperative chemotherapy is increasingly
employed in operable breast cancer. Response or resistance can-
not be predicted and treatment time may be lost if an ineffective
regimen is selected. At our institute, prospective clinical trials
were designed to identify gene expression patterns predicting
response to preoperative chemotherapy in breast cancer patients.
Methods: Patients with operable or locally advanced breast can-
cer were either included in a randomized phase II study or
received neoadjuvant chemotherapy off protocol. Treatment reg-
imens were chosen dependent on the HER2 status of the tumor
and response was evaluated by MRI. From all patients 14G core
needle biopsies were taken before treatment and total RNA was
isolated. Amplified mRNA was labeled and hybridized to 35k
human oligo microarrays from our microarray facility.
Results: From 48 patients good quality RNA from biopsy tissue
with more than 50% tumor cells was isolated. In a training set
containing 11 pathological complete remissions (pCR) and 9
non-responders (NR) we were able to separate these groups by
using 20 genes in a supervised classification with Euclidian dis-
tance and a 9-step cross validation. These results could be vali-
dated in an independent set of 11 samples (6 pCR, 5 NR). From
10 out of 11 samples, response status could be predicted correctly,
independent from the treatment regimen administered. Although
ER-positive tumors have a lower pCR rate than ER-negative ones,
the steroid hormone receptors were not present in the classifier.
Conclusions: Neoadjuvant chemotherapy studies provide a good
setting to identify gene expression profiles associated with response
to specific regimens. Large series of patients (>100) are required to
obtain reliable and reproducible gene expression signatures.
doi:10.1016/j.ejcsup.2006.04.132
